ChemicalBook > CAS DataBase List > CTS-1027

CTS-1027

Product Name
CTS-1027
CAS No.
193022-04-7
Chemical Name
CTS-1027
Synonyms
RS130830;CTS-1027;RS-130830;Ro1130830;RS 130830;Ro-1130830;Ro 1130830;RS 130830, Ro-1130830;RS 130830;RO 1130830;CTS1027;CTS 1027;RS130830;RO1130830;RS-130830;RO-1130830;4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide
CBNumber
CB62624116
Molecular Formula
C19H20ClNO6S
Formula Weight
425.88
MOL File
193022-04-7.mol
More
Less

CTS-1027 Property

Density 
1.388±0.06 g/cm3(Predicted)
storage temp. 
Inert atmosphere,Store in freezer, under -20°C
solubility 
Soluble in DMSO
form 
A solid
pka
9.27±0.23(Predicted)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
INB0001538
Product name
RS-130830
Purity
95.00%
Packaging
5MG
Price
$386.1
Updated
2021/12/16
ChemScene
Product number
CS-0281
Product name
CTS-1027
Purity
98.45%
Packaging
10mg
Price
$396
Updated
2021/12/16
ApexBio Technology
Product number
A3334
Product name
CTS-1027
Packaging
10mg
Price
$483
Updated
2021/12/16
American Custom Chemicals Corporation
Product number
INB0001538
Product name
RS-130830
Purity
95.00%
Packaging
25MG
Price
$750.75
Updated
2021/12/16
ChemScene
Product number
CS-0281
Product name
CTS-1027
Purity
98.45%
Packaging
50mg
Price
$1162
Updated
2021/12/16
More
Less

CTS-1027 Chemical Properties,Usage,Production

Biological Activity

CTS-1027 is a potent MMP inhibitor with IC50 values of 0.3 nM and 0.5 nM for MMP2 and MMP13, respectively.

in vivo

CTS-1027 significantly reduces the hepatocyte apoptosis, features of cholestatic liver injury, amd markers of hepatic fibrogenesis in the BDL mouse. It improves overall animal survival following 14 days of BDL in mice. In male animals treated for 8 weeks the terminal plasma concentration of RS-130830 is 311±45 nM. Treatment of male mice with RS-130830 for 8 weeks causes an 89% increase in plasma triglyceride concentration, but there is no corresponding effect in female mice treated for 12 Plaque. The lipid content of animals receiving RS-130830 is increased by 81% at 12 weeks, and increased by 41% at 16 weeks.

div>

target

IC50: 0.2 nM (MMP2), 0.5 nM (MMP13), 0.7 nM (MMP12), 0.9 nM (MMP8), 9.5 nM (MMP3), 15 nM (MMP14)

CTS-1027 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

CTS-1027 Suppliers

China 61 United States 10 Global 71
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2784
Advantage
58
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4662
Advantage
60
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
19892
Advantage
58
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6393
Advantage
58
Tel
+1-833-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
52927
Advantage
58
Tel
16314854226
Email
info@bocsci.com
Country
United States
ProdList
9926
Advantage
65
More
Less

View Lastest Price from CTS-1027 manufacturers

Career Henan Chemical Co
Product
CTS-1027 193022-04-7
Price
US $1.00/g
Min. Order
1g
Purity
99%
Supply Ability
200kg
Release date
2020-01-14

193022-04-7, CTS-1027Related Search:

TRIMETHOXY(PENTAFLUOROPHENYL)SILANE Phenyltriethoxysilane Trimethoxypropylsilane Y16 TENOVIN-1 LY 303511 (hydrochloride) PFK-015 CCT 137690 TG101209 BIX 02189 BMS 833923 MS436 CNX-1351 Mutant IDH1 inhibitor

  • CTS-1027
  • 2H-Pyran-4-carboxaMide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]Methyl]tetrahydro-N-hydroxy-
  • Ro 1130830
  • Ro1130830
  • Ro-1130830
  • RS 130830
  • RS130830
  • RS-130830
  • 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide
  • RS 130830;RO 1130830;CTS1027;CTS 1027;RS130830;RO1130830;RS-130830;RO-1130830
  • RS 130830, Ro-1130830
  • 193022-04-7